The following points are a high-level overview, not a complete list of risks or precautions
4, 2025, pp
Non-linear fit curves of the AUCs were used to generate dose responses using GraphPad Prism 10
The conversation covers how our understanding of obesity as a chronic, relapsing disease has changed over the past 30 years, what the new clinical versus preclinical obesity framework means for how we diagnose and treat it, how GLP-1 drugs work and why they've succeeded where earlier medications failed, what the STEP and SELECT trials revealed about the disease-modifying potential of semaglutide, and how patients and clinicians should be thinking about who these drugs are really for
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks